Karim F.
- Country
- France
- Department
- Oncologie Médical
Research Overview
- Phase I First-in-Human Study of DS9051b in Patients with Advanced/Metastatic Adrenocortical Carcinoma and Metastatic Castration‑Resistant Prostate Cancer
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- Phase 1 Study of Valemetostat and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 78 of 245 partner sites.
Specializations
Advanced Prostate Cancer Treatment
This investigator specializes in treating metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), with particular focus on innovative therapeutic approaches.
- Novel hormone therapy combinations
- Targeted radiotherapy treatments
- Molecular-based therapies
Precision Medicine Applications
The investigator focuses on personalized treatment approaches utilizing specific genetic and molecular markers, including studies involving PTEN-deficient tumors and DDR gene mutations.
- Biomarker-driven therapies
- PSMA-targeted treatments
- Genetic mutation analysis
Urological Oncology
Research extends to various urological cancers, including germ cell tumors and high-risk localized prostate cancer, with emphasis on treatment optimization and risk assessment.
- Treatment resistance mechanisms
- Combination therapy approaches
- Risk stratification methods
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.